DT Midstream reports Q2 results on July 30 with the Street broadly constructive but the stock sitting just below the consensus target, making the quality of management's guidance the real test.
The options market is not signaling alarm. The put/call ratio has edged up to 0.062 — modestly above its 20-day average of 0.053, roughly 1.4 standard deviations out — but remains extraordinarily low in absolute terms, near the bottom of its 52-week range. That tells a story of almost no hedging demand into the print. The borrow market confirms the relaxed tone: availability runs above 1,000%, meaning there are far more shares available to lend than currently borrowed. Cost to borrow is just 0.43%, down nearly 18% on the week. Short interest has drifted up about 14% over the past month to 3.85% of the free float, but with days-to-cover at 6.7 and borrow this loose, there is no squeeze dynamic in play. The stock itself has barely moved — down less than 1% on the month to $145.69, with a 0.4% gain on the week broadly in line with peers like KMI (+1.7%) and WMB (+0.8%).
The bull and bear cases are well-defined. On the positive side, DTM's $3.4 billion organic project backlog grew 50%, and a 5–7% annual dividend growth target is underwritten by take-or-pay contracts that insulate cash flows from commodity moves — a point reinforced by the stock's dividend factor score ranking in the 94th percentile. Jefferies raised its target to $170 on July 16, and JP Morgan lifted its target to $154 earlier this month, both maintaining existing ratings — a signal that the Street sees upside from $145.69 but is not rushing to upgrade. The bear concern is leverage: $3.32 billion in debt, heavy exposure to Expand Energy, and asset concentration in Haynesville and the Northeast leave the company exposed if volumes disappoint or interest costs rise. Goldman Sachs carries a Sell with a $127 target, the clearest dissenting voice. The mean target of $156.50 implies modest upside, while valuation looks stretched — EV/EBITDA near 14.5x and a P/E of 29.7x are not cheap for a fee-based infrastructure business.
One institutional note worth flagging: T. Rowe Price added over 1.5 million shares in the quarter through June, making it among the most active buyers in the holder list. Tortoise Capital also added nearly 395,000 shares. That kind of sector-specialist buying is consistent with the bull thesis on backlog growth and dividend visibility, even at these multiples. Past earnings prints have not offered much by way of dramatic reactions — the May 2026 event produced a one-day move of just -1.6%, and the five-day drift was similarly contained — suggesting the market tends to digest DTM results without major repricing.
Wednesday's print is therefore less about whether DTM is growing and more about whether management can deliver concrete guidance on backlog conversion and leverage trajectory that justifies a stock trading within $10 of its consensus target with valuation already running full.
See the live data behind this article on ORTEX.
Open DTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
